$PLSE
Pulse Biosciences Inc

2021 Q3 Form 10-Q Financial Statement

#000162510121000042 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $574.0K $0.00 $0.00
YoY Change
Cost Of Revenue $727.0K
YoY Change
Gross Profit -$153.0K
YoY Change
Gross Profit Margin -26.66%
Selling, General & Admin $7.660M $7.047M $5.320M
YoY Change 32.76% 32.46% 3.3%
% of Gross Profit
Research & Development $6.460M $7.459M $5.870M
YoY Change -7.29% 27.07% -7.37%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $6.460M $14.81M $11.35M
YoY Change -49.94% 30.4% -2.53%
Operating Profit -$14.27M -$14.81M
YoY Change 10.6%
Interest Expense -$9.000K $517.0K $20.00K
YoY Change -200.0% 2485.0% -93.1%
% of Operating Profit
Other Income/Expense, Net -$9.000K -$517.0K
YoY Change -200.0%
Pretax Income -$14.28M -$15.32M -$11.33M
YoY Change 10.71% 35.24% -0.26%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.30M -$15.32M -$11.33M
YoY Change 10.89% 35.21% -0.23%
Net Earnings / Revenue -2491.29%
Basic Earnings Per Share -$0.48 -$0.58
Diluted Earnings Per Share -$482.3K -$0.58 -$526.2K
COMMON SHARES
Basic Shares Outstanding 29.61M 26.48M 20.87M
Diluted Shares Outstanding 29.61M 26.48M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.99M $47.43M $37.77M
YoY Change 41.91% 25.57% -11.42%
Cash & Equivalents $41.99M $47.43M $37.77M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $2.866M $3.267M $910.0K
YoY Change 282.13% 259.01% -52.36%
Inventory $4.281M $2.691M
Prepaid Expenses
Receivables $72.00K
Other Receivables $0.00
Total Short-Term Assets $49.21M $61.76M $38.67M
YoY Change 62.23% 59.69% -13.19%
LONG-TERM ASSETS
Property, Plant & Equipment $2.446M $2.460M $2.591M
YoY Change -4.53% -5.06% 30.53%
Goodwill $2.791M $2.791M $2.791M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $365.0K $365.0K $365.0K
YoY Change 0.0% 0.0% -77.81%
Total Long-Term Assets $17.94M $18.28M $19.71M
YoY Change -7.35% -7.23% 57.89%
TOTAL ASSETS
Total Short-Term Assets $49.21M $61.76M $38.67M
Total Long-Term Assets $17.94M $18.28M $19.71M
Total Assets $67.15M $80.04M $58.38M
YoY Change 35.12% 37.1% 2.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.706M $2.823M $1.489M
YoY Change 88.97% 89.59% -5.58%
Accrued Expenses $4.971M $4.572M $3.123M
YoY Change 20.92% 46.4% 83.38%
Deferred Revenue $7.000K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.086M $1.730M
YoY Change
Total Short-Term Liabilities $9.519M $9.844M $4.890M
YoY Change 58.65% 101.31% 41.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.24M $10.45M $11.16M
YoY Change -6.81% -6.41% 200.0%
Total Long-Term Liabilities $10.24M $10.45M $11.16M
YoY Change -6.81% -6.41% 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.519M $9.844M $4.890M
Total Long-Term Liabilities $10.24M $10.45M $11.16M
Total Liabilities $19.76M $20.29M $16.05M
YoY Change 16.3% 26.38% 123.84%
SHAREHOLDERS EQUITY
Retained Earnings -$220.8M -$206.5M -$145.9M
YoY Change 39.04% 41.54% 50.17%
Common Stock $268.2M $266.3M $188.2M
YoY Change 40.04% 41.46% 28.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.39M $59.75M $42.33M
YoY Change
Total Liabilities & Shareholders Equity $67.15M $80.04M $58.38M
YoY Change 35.12% 37.1% 2.37%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$14.30M -$15.32M -$11.33M
YoY Change 10.89% 35.21% -0.23%
Depreciation, Depletion And Amortization $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$13.35M -$16.36M -$7.940M
YoY Change 56.14% 106.08% -18.06%
INVESTING ACTIVITIES
Capital Expenditures -$157.0K -$96.00K $70.00K
YoY Change 161.67% -237.14% -216.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $8.010M
YoY Change -100.0% -100.0% -36.53%
Cash From Investing Activities -$157.0K -$96.00K $8.080M
YoY Change -99.3% -101.19% -35.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.072M 4.002M 29.76M
YoY Change 1777.21% -86.55% -4978.69%
NET CHANGE
Cash From Operating Activities -13.35M -16.36M -7.940M
Cash From Investing Activities -157.0K -96.00K 8.080M
Cash From Financing Activities 8.072M 4.002M 29.76M
Net Change In Cash -5.435M -12.46M 29.90M
YoY Change -82.29% -141.66% 1228.89%
FREE CASH FLOW
Cash From Operating Activities -$13.35M -$16.36M -$7.940M
Capital Expenditures -$157.0K -$96.00K $70.00K
Free Cash Flow -$13.19M -$16.27M -$8.010M
YoY Change 55.39% 103.08% -16.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001625101
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
plse Directors And Officers Liability Insurance Period
DirectorsAndOfficersLiabilityInsurancePeriod
P1Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
dei Entity Address Address Line1
EntityAddressAddressLine1
3957 Point Eden Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
906-4600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
PLSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29605930
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47426000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2020Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
8012000
CY2021Q2 us-gaap Inventory Net
InventoryNet
2691000
CY2021Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
8371000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1223000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3267000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
641000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
61755000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
22339000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2460000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3549000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2021Q2 us-gaap Goodwill
Goodwill
2791000
CY2020Q4 us-gaap Goodwill
Goodwill
2791000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9119000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9438000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2021Q2 us-gaap Assets
Assets
80039000
CY2020Q4 us-gaap Assets
Assets
41293000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2823000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1717000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4572000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
719000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1730000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9844000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7585000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10445000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10814000
CY2021Q2 us-gaap Liabilities
Liabilities
20289000
CY2020Q4 us-gaap Liabilities
Liabilities
18399000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29606000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29606000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25550000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25550000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
29000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
266223000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195410000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206502000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172540000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80039000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41293000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7459000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5870000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16522000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12051000
CY2021Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3147000
CY2020Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1485000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
7293000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3180000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4200000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3999000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9516000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8073000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
14806000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11354000
us-gaap Operating Expenses
OperatingExpenses
33331000
us-gaap Operating Expenses
OperatingExpenses
23304000
CY2021Q2 us-gaap Interest Expense
InterestExpense
517000
CY2020Q2 us-gaap Interest Income Operating
InterestIncomeOperating
21000
us-gaap Interest Expense
InterestExpense
631000
us-gaap Interest Income Operating
InterestIncomeOperating
99000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-517000
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-631000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
99000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15323000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11333000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
us-gaap Net Income Loss
NetIncomeLoss
-23205000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15323000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11350000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33961000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23209000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26477000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21528000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26276000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21183000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
us-gaap Net Income Loss
NetIncomeLoss
-23205000
us-gaap Depreciation
Depreciation
229000
us-gaap Depreciation
Depreciation
213000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Share Based Compensation
ShareBasedCompensation
9413000
us-gaap Share Based Compensation
ShareBasedCompensation
5038000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-13000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-119000
plse Gain Loss On Government Securities
GainLossOnGovernmentSecurities
8000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2691000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2454000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-522000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-23000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-319000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-198000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-129000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1041000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-758000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-754000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
393000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-192000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-110000
plse Increase Decrease Interest On Related Party Note
IncreaseDecreaseInterestOnRelatedPartyNote
629000
plse Increase Decrease Other Assets
IncreaseDecreaseOtherAssets
424000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28053000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17561000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3006000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
17000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4510000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7854000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18404000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
421000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
255000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4217000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
678000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48348000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29759000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1730000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
232000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55162000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30023000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
34963000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
30866000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47426000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37765000
us-gaap Contribution Of Property
ContributionOfProperty
65000
us-gaap Contribution Of Property
ContributionOfProperty
257000
us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
1000
us-gaap Available For Sale Securities Transfers To Trading Gains Losses Net
AvailableForSaleSecuritiesTransfersToTradingGainsLossesNet
-4000
us-gaap Stock Issued1
StockIssued1
629000
plse Related Party Other Receivable From Issuance Of Common Stock From Private Placement Equity Offering
RelatedPartyOtherReceivableFromIssuanceOfCommonStockFromPrivatePlacementEquityOffering
8371000
plse Other Receivable From Issuance Of Common Stock From At Market Equity Offering
OtherReceivableFromIssuanceOfCommonStockFromAtMarketEquityOffering
25000
plse Issuance Costs For Rights Offering In Accounts Payable
IssuanceCostsForRightsOfferingInAccountsPayable
261000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
20397000
CY2021Q2 plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
59000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49941000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2469000
CY2021Q2 plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
59000
CY2021Q2 plse Issuance Of Common Stock In At Market Equity Offering
IssuanceOfCommonStockInAtMarketEquityOffering
-232000
CY2021Q2 plse Adjustment To Shares Issued Under Employee Stock Purchase Plan
AdjustmentToSharesIssuedUnderEmployeeStockPurchasePlan
9000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2448000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15323000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
59000
plse Issuance Of Common Stock As Part Of Debt Extinguishment And Private Investment Net Of Issuance Cost
IssuanceOfCommonStockAsPartOfDebtExtinguishmentAndPrivateInvestmentNetOfIssuanceCost
49941000
plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
3334000
plse Issuance Of Common Stock In At Market Equity Offering
IssuanceOfCommonStockInAtMarketEquityOffering
7432000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
421000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-232000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9413000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
21768000
CY2020Q2 plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
501000
CY2020Q2 plse Stock Issued During Period Value Rights Offering
StockIssuedDuringPeriodValueRightsOffering
29498000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2412000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11333000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
42328000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
30737000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
255000
plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
501000
plse Stock Issued During Period Value Rights Offering
StockIssuedDuringPeriodValueRightsOffering
29498000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5038000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
us-gaap Net Income Loss
NetIncomeLoss
-23205000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
42328000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the condensed consolidated financial statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5917397
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6060320
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
44279000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17192000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q2 plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
665000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4605000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4394000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2145000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1916000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2460000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2020Q2 us-gaap Depreciation
Depreciation
100000
CY2021Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
200000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4436000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4103000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3549000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
333000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
556000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3549000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3353000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3324000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1563000
CY2021Q2 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
312000
CY2020Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
188000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
74000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
87000
CY2021Q2 plse Controlled Launch
ControlledLaunch
563000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
270000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4572000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2014Q4 us-gaap Goodwill
Goodwill
2800000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5039194
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
976078
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44981
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
80029
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
62738
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5827524
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.64
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3042982
CY2021Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
16.00
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2448000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2412000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9413000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5038000
CY2021Q2 plse Director And Officer Insurance Premium Payable
DirectorAndOfficerInsurancePremiumPayable
2600000
CY2021Q2 plse Insurance Down Payment
InsuranceDownPayment
700000
CY2021Q2 plse Financed Insurance Policy Balance
FinancedInsurancePolicyBalance
1900000
CY2021Q2 plse Financed Insurance Policy Interest Rate
FinancedInsurancePolicyInterestRate
0.0369
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
894000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1806000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1845000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1910000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1976000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2046000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6191000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16668000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5504000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11164000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
719000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10445000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11164000
us-gaap Operating Lease Payments
OperatingLeasePayments
749000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M2D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
plse Number Of Kols
NumberOfKols
80
plse Number Of Patients Participating In Procedure
NumberOfPatientsParticipatingInProcedure
40 or 50
CY2021Q2 plse Program Expenses
ProgramExpenses
400000
plse Program Expenses
ProgramExpenses
600000

Files In Submission

Name View Source Status
0001625101-21-000042-index-headers.html Edgar Link pending
0001625101-21-000042-index.html Edgar Link pending
0001625101-21-000042.txt Edgar Link pending
0001625101-21-000042-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20210630.xsd Edgar Link pending
plse-20210630x10q.htm Edgar Link pending
plse-20210630x10q_htm.xml Edgar Link completed
plse-20210630xex31_1.htm Edgar Link pending
plse-20210630xex31_2.htm Edgar Link pending
plse-20210630xex32_1.htm Edgar Link pending
plse-20210630_cal.xml Edgar Link unprocessable
plse-20210630_def.xml Edgar Link unprocessable
plse-20210630_lab.xml Edgar Link unprocessable
plse-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending